FDA approves allergy drug Xyzal

WASHINGTON The Food and Drug Administration has approved an oral solution version of Xyzal, the allergy drug developed by Sanofi-Aventis and UCB, according to published reports. The drug will be available in a 0.5 mg/mL oral solution.

The companies had received FDA approval for Xyzal in a tablet form last May. Sanofi-Aventis said both forms of the drug are now approved for use by adults and children over six years old. The companies signed the agreement for the drug in September 2006.

Xyzal is a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronicidiopathic urticaria.